APF530
Term · Oncology and biomedicine · MLC-T-ONC-011197
A controlled-release formulation of a biodegradable poly(ortho ester) polymer, encapsulating the indazole derivative granisetron, with antiemetic activity. Upon administration of APF530, the polymer slowly erodes and releases the active ingredient granisetron. As a selective serotonin receptor antagonist, granisetron competitively blocks the action of serotonin at 5-hydroxytryptamine3 (5-HT3) receptors, resulting in the suppression of nausea and vomiting over a sustained period of time.
| Identifier | MLC-T-ONC-011197 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | APF-530 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-011197",
"term": "APF530",
"field": "Oncology and biomedicine",
"definition": "A controlled-release formulation of a biodegradable poly(ortho ester) polymer, encapsulating the indazole derivative granisetron, with antiemetic activity. Upon administration of APF530, the polymer slowly erodes and releases the active ingredient granisetron. As a selective serotonin receptor antagonist, granisetron competitively blocks the action of serotonin at 5-hydroxytryptamine3 (5-HT3) receptors, resulting in the suppression of nausea and vomiting over a sustained period of time.",
"synonyms": [
"APF-530"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/apf530/"
}
Record 2,366 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.